DCISionRT, the Only DCIS Test to Predict Radiation Therapy Benefit

Important DCISionRT Information for Physicians and Patients

  • Dr. Anushka Patel
  • Dr. Christy Kesslering

For Doctors

The Test

For Patients

preludedx dcisionrt logo

The DCIS Test That Enables Personalized Treatment

dcisionrt personalized treatment vertical

DCISionRT enables physicians to deliver precision medicine to DCIS patients

Radiotherapy chart

Validated across multiple cohorts, DCISionRT is the only DCIS test that can identify a truly low risk group of patients who can safely omit radiation therapy:

  1. Patients in the DS Low Risk group receive a statistically non-significant benefit from radiation.
  2. Patients within the DS Elevated Risk group see a targeted benefit from RT.
10 year total risk chart

DCISionRT identified patients with 3 distinct risk profiles:

  1. Low Risk patients with a low recurrence risk with or without adjuvant RT.
  2. Elevated Risk patients with significant benefit to recurrence risk with adjuvant RT.
  3. Residual Risk patient with an excessive recurrence risk remaining after BCS+RT, potentially warranting intensified or alternative treatment approaches.
Radiotherapy chart
10 year total risk chart

Validated across multiple cohorts, DCISionRT is the only DCIS test that can identify a truly low risk group of patients who can safely omit radiation therapy:

  1. Patients in the DS Low Risk group receive a statistically non-significant benefit from radiation.
  2. Patients within the DS Elevated Risk group see a targeted benefit from RT.

DCISionRT identified patients with 3 distinct risk profiles:

  1. Low Risk patients with a low recurrence risk with or without adjuvant RT.
  2. Elevated Risk patients with significant benefit to recurrence risk with adjuvant RT.
  3. Residual Risk patient with an excessive recurrence risk remaining after BCS+RT, potentially warranting intensified or alternative treatment approaches.
  1. Bremer, TM et al. A biologic signature for breast ductal carcinoma in situ to predict radiation therapy (RT) benefit and assess recurrence risk, Clinical Cancer Research 2018, Published Online 12/01/2018
  2. Weinmann, S et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiation therapy, Clinical Cancer Research 2020, Published Online 4/27/2020
  3. Warnberg et al. Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma in Situ (DCIS) of the Breast in a Randomized Clinical Trial (SweDCIS). Cancers 2021.
  4. Vicini,F et al. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. IJROBP 2022, Published Online 09/15/2022